Mark Zitter, Founder and CEO of The Zitter Group, in San Francisco and Millburn, NJ, and Chairman of Vital Decisions, talks about the company's telephone counseling service aimed lowering costs by assisting end-of-life oncology patients with making informed decisions about their care.
Mr. Zitter also discusses how Vital Decisions works with private and government payers, in addition to terminal cancer patients, with the overarching goal of eliminating unnecessary costs and care that these patients may not want or need. Once a patient reaches a final decision, the company assists with communicating the patient's wishes to their family and medical team.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More